"Coinbase is an ideal platform for STSS as it seeks to leverage its digital asset treasury strategy to help advance decentralized finance," said James Zhang, Strategic Advisor to STSS. "By utilizing Coinbase's suite of products, STSS can enjoy the institutional-grade infrastructure, deep liquidity, and competitive pricing required to effectively manage a leading Solana treasury." , /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ: STSS) and Coinbase Global, Inc ("Coinbase"), one of ...

Stockholders’ Equity & Liquidity Show Substantial ImprovementsSCOTTSDALE, Ariz., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Caliber (Nasdaq: CWD), a diversified real estate and digital asset platform, today announced certain estimated preliminary financial results for the third quarter ended September 30, 2025. "Our estimated Third Quarter results highlight a dramatically improved balance sheet driven by our DAT strategy,” said Chris Loeffler, Chief Executive Officer of Caliber, “The material quarter over quarter im ...

Investment creates the world’s first Strategic Compute Reserve  Strategy complements Predictive Oncology’s AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) (Nasdaq: POAI) today announced the closing of two previously announced private investment in public equity transactions (“PIPEs”) totaling approximately $343.5 million to support the Company’s adoption of a digital asset treasury strategy ...

MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its launch of a new digital asset treasury strategy focused on top-tier cryptocurrency assets. MAIA’s Board of Directors has a ...

Leap Therapeutics Inc. (NASDAQ:LPTX) is trading at $0.69 in pre-market, down 9.15% on Tuesday.Check out the current price of LPTX stock here.Winklevoss Capital Leads $58.9 Million Private PlacementThe Cambridge, Massachusetts-based biotechnology company announced $58.88 million in cash commitments for a private investment in public equity offering led by Winklevoss Capital. According to an Oct. 6 press release, the deal involves 95,849,353 common shares or pre-funded warrants, along with warrants to purchas ...

Financial Data and Key Metrics Changes - Total revenue for the first half of 2025 was $18.7 million, representing a 37% increase year-on-year [4][22] - Gross profit increased by 17% to $15.1 million, with a gross margin maintained at 80% [7][22] - EBITDA was reported at $5.2 million, reflecting top-line growth and continued investment [5][21] - Net profit after tax was $4.66 million, with a net margin of 35% [7][22] - Interest income rose to $1.3 million from $0.7 million a year ago, driven by a larger loan receivable base [7][22] Business Line Data and Key Metrics Changes - The technology segment generated $9.3 million in revenue, up from $1.7 million a year ago, indicating a structural shift towards technology as a growth driver [3][18] - Consultancy revenue contributed $8.1 million, showing stability despite a return to typical activity levels after an exceptional 2024 [3][18] Market Data and Key Metrics Changes - The company is expanding into GPU-as-a-Service with the upcoming launch of the SecureGPU and GPU cloud platform [4][19] - There is consistent interest from enterprise clients in AI-integrated server and cloud platforms, with discussions moving into later stages [11][26] Company Strategy and Development Direction - The company is focused on building a portfolio of high-growth verticals across cybersecurity, AI, fintech, and technology development [3][18] - A planned IPO of VCCG, the capital market advisory arm, is targeted for the first quarter of 2026, reflecting strategic flexibility [4][19] Management's Comments on Operating Environment and Future Outlook - Management emphasized a disciplined approach to capital allocation, prioritizing AI infrastructure and related services [9][24] - The company is focused on execution and scaling, with a clear strategy to convert initiatives into sustained earnings growth [5][21] Other Important Information - The company is in advanced discussions regarding a digital asset treasury strategy to complement its ecosystem [4][19] - The first half results reflect a scalable, margin-creating model supported by diversified revenue streams [8][23] Q&A Session Summary Question: How is capital allocation prioritized across AI, cybersecurity, fintech, and data analytics? - The company prioritizes AI infrastructure and related services, followed by cybersecurity, while being selective in fintech and data analytics investments [9][24] Question: Is the moderation in consultancy revenue a structural shift or cyclical effect? - It is both; consultancy had a strong 2024, and there is a structural shift with technology becoming a larger part of the business [10][25] Question: How is the current pipeline shaping for the second half of the year, particularly in technology? - The pipeline looks steady, with consistent interest in AI-integrated server and cloud platforms, and healthy consultancy mandates [11][26][28] Question: What key execution risks are being monitored for the remainder of 2025? - Key risks include delivery capacity, timing of consultancy deal closures, capital deployment discipline, and regulatory developments [13][29]

, /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the ...

Core Insights - Helius Medical Technologies, Inc. has announced the acquisition of over 2.2 million Solana (SOL) tokens as part of its digital asset treasury strategy, with cash holdings exceeding $15 million, bringing the total value of its combined holdings to over $525 million [1][2][8] Group 1: Company Strategy - The company is committed to its Solana treasury strategy, reflecting long-term confidence in the Solana ecosystem [2] - HSDT's strategy is focused on maximizing shareholder value through efficient accumulation of Solana tokens, with current holdings exceeding the initial capital raise amount in less than three weeks [3] - The company aims to support the growth and security of tokenized networks by being a long-term holder of SOL while continuing its neurotech and medical device operations [5][8] Group 2: Market Position and Performance - Solana is recognized as the fastest growing blockchain, leading in transaction revenue and processing over 3,500 transactions per second, with an average of 3.7 million daily active wallets [5] - The Solana network has surpassed 23 billion transactions year to date and offers a ~7% native staking yield, making it financially productive compared to non-yield-bearing assets like Bitcoin [5] - There is strong interest from institutional investors, particularly from Asia, following recent digital asset conferences, indicating a growing market presence for HSDT [4]

The report, including disclosures, can be found here. Important Note Regarding Analyst Reports Please note that any opinions, estimates or forecasts regarding TNL Mediagene's performance made by research analysts, including Sidoti, are theirs alone and do not represent opinions, forecasts or predictions of TNL Mediagene or its management. TNL Mediagene does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Accessibilit ...

Accessibility StatementSkip Navigation Prosek Partners for Sharps Technology[email protected] NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ: STSS) today announced a stock repurchase program to acquire up to $100 million of the company's outstanding common stock. This new stock repurchase program will enable the company to repurchase its shares in the open market and in negotiated transactions. STSS previously announced its plans to establish a Solanadigit ...